A possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil has been reported. - GreenMedInfo Summary
Abstract Title:
Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil.
Abstract Source:
J Intern Med. 1996 Dec ;240(6):403-4. PMID: 9010388
Article Affiliation:
Netherlands Pharmacovigilance Foundation LAREB, Tilburg, The Netherlands.
Abstract:
The occurrence of rhabdomyolysis is one of the rare side-effects of the cholesterol-lowering agent simvastatin. During the use of lovastatin, an agent related to simvastatin, the risk of this side-effect might be increased when cyclosporin or gemfibrozil are used concomitantly. It is possible that this also applies for simvastatin. We present two patients who developed rhabdomyolysis during the concomitant use of simvastatin and gemfibrozil.
Article Published Date : Dec 01, 1996
Study Type : Human: Case Report
Additional Links
Additional Keywords : Drug Synergy : CK(381) : AC(167)
Problem Substances : Fenofibrates : CK(133) : AC(19), Gemfibrozil : CK(3) : AC(1), Simvastatin : CK(791) : AC(164)
Adverse Pharmacological Actions : Myotoxicity : CK(327) : AC(80)
